Relugolix is the first and only, orally-administered GnRH receptor antagonist approved for the treatment of several hormone-responsive conditions, including prostate cancer - similar therapies require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients


Product Name Relugolix
CAS Number 737789-87-6
Therapeutic Class Anti-endometriosis, Antineoplastic
Dosage Form Oral Tablet
Availability Under Evaluation
Regulatory Status